Compare Nucor Corporation (NUE) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs Pfizer Inc — how do they compare? Nucor Corporation trades at $248.12 (market cap $55.84B), while Pfizer Inc trades at $27.93 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 2.8× Nucor Corporation's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Nucor Corporation for 78 Days and Pfizer Inc for 158 Days on average.
| NUE | PFE | |
|---|---|---|
Market Cap | $55.84B | $158.56B |
Volume | 848,835 | 44,138,282 |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $29.02 |
52-Week Low | $131.78 | $23.67 |
Typical Hold Time | 78 Days | 158 Days |
Enterprise Value | $60.25B | $210.06B |
Dividend Yield | 0.91% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $246.44, down 1.84% on the day, with a neutral technical signal and mixed earnings history including a Q2 2026 beat. Revenue and net income have shown volatility, with 2025 revenue at $32.49B and net income at $1.74B, while analyst consensus is a 'Buy' with a $266.88 price target. Recent news highlights steel sector dynamics and Nucor's Q3 2026 earnings guidance.
The outlook for NUE is cautiously optimistic, supported by analyst bullishness and projected earnings growth, but risks include competitive pressures from new steel capacity and cyclical demand fluctuations. Investment opportunity lies in its solid fundamentals and dividend history, though investors should weigh margin pressures and market volatility.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
